| BSE: 532331 | Sector: Health care |
| NSE: AJANTPHARM | ISIN Code: INE031B01049 |
| BSE 00:00 | 22 Jun | 1035.30 |
-7.65 (-0.73%) |
OPEN
1033.00 |
HIGH
1044.95 |
LOW
1005.00 |
| NSE 00:00 | 22 Jun | 1038.30 |
-4.40 (-0.42%) |
OPEN
1041.70 |
HIGH
1046.60 |
LOW
1004.60 |
| OPEN | 1033.00 |
| PREVIOUS CLOSE | 1042.95 |
| VOLUME | 41137 |
| 52-Week high | 1592.00 |
| 52-Week low | 897.60 |
| P/E | 21.32 |
| Mkt Cap.(Rs cr) | 9,111 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
9.28 pm | 23 Jun 2018 | Press Trust of India
Biocon said that it is committed to global standards of quality and compliance in a BSE filing after receiving the Establishment Inspection Report
10.05 am | 22 Jun 2018 | Business Standard
The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a canc...
12.41 am | 21 Jun 2018 | Business Standard
The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products
11.44 pm | 20 Jun 2018 | Business Standard
Synergy benefits from acquisition of Unichem's products may raise earnings
10.23 am | 20 Jun 2018 | Business Standard
Thus far in the calendar year 2018, the stock of this pharmaceutical company has zoomed 107% from Rs 1,289, as compared to 4% rise in the S&P BSE Sens...
9.45 am | 20 Jun 2018 | Business Standard
The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.
9.57 pm | 19 Jun 2018 | Business Standard
Market size of drug is $40 mn. Having a manufacturing footprint in the US is part of company's game plan to mitigate regulatory risk
4.17 pm | 19 Jun 2018 | Press Trust of India
The drug has been approved by the US Food and Drug Administration
11.53 pm | 16 Jun 2018 | Business Standard
The court has scheduled an expedited hearing of the preliminary injection for Thursday (June 28) and a ruling is expected soon after
1.37 pm | 16 Jun 2018 | Business Standard
Dr Reddy's recently announced the launch of Buprenophine and Naloxone Sublingual Film, a generic equivalent of Suboxone
11.22 pm | 15 Jun 2018 | IANS
FHL informed BSE in a filing, that its board has decided to withdraw the 'arrangement and amalgamation between the company, Fortis Malar Hospitals, SR...
11.22 pm | 15 Jun 2018 | IANS
FHL informed BSE in a filing, that its board has decided to withdraw the 'arrangement and amalgamation between the company, Fortis Malar Hospitals, SR...
10.49 pm | 15 Jun 2018 | Business Standard
Mylan Technologies Inc too has received the FDA nod for the same drug Suboxone (buprenorphine and naloxone) sublingual film in multiple strengths.
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
12.22 pm | 15 Jun 2018 | Business Standard
At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.
9.50 am | 15 Jun 2018 | Business Standard
In past eight trading sessions, the stock of pharmaceutical company has rallied 20% from Rs 1,960 on June 5, 2018, as compared to 2% rise in the S&P B...
9.20 pm | 14 Jun 2018 | Business Standard
The Fortis Malar stock reacted positively to the decision and the scrip closed at Rs 51.85 a share
